EuBiologics KRX:206650KOSDAQ

유바이오로직스 · Korean news coverage and regulatory filings, organized.

Articles, 24h5
Articles, 7 days23
DART filings, 7 days1
Articles tracked42since Sep 11

In Q2 2026, EuBiologics reported revenue of ₩33.2bn, down 8.3% year on year, and operating profit of ₩8.6bn. EuBiologics (유바이오로직스) appeared in 23 Korean news articles and 1 DART filing over the past seven days. Coverage peaked on Oct 26 with 11 articles. The most common catalyst was clinical & approvals (7). It was most often mentioned alongside 글로벌테크놀로지.

Filing signals Op. margin 20%+ Supply contract Clinical trial filing Screener

EuBiologics quarterly results separate, KRW

QuarterRevenueYoYOperating profitNet income
Q2 2026₩33.2bn-8.3%₩8.6bn
margin 25.8%
₩7.5bn
Q1 2026₩15.6bn-60.4%₩2.2bn
margin 14.0%
₩3.7bn
Q4 2025 derived₩32.3bn-12.2%₩13.6bn
margin 42.1%
₩414m
Q3 2025₩41.1bn+13.7%₩18.9bn
margin 46.0%
₩17.4bn
Q2 2025₩36.2bn+360.6%₩11.2bn
margin 31.0%
₩7.7bn
Q1 2025₩39.5bn+160.1%₩16.9bn
margin 42.8%
₩15.7bn
Q4 2024 derived₩36.8bn+36.9%₩16.6bn
margin 45.1%
₩8.2bn
Q3 2024₩36.2bn+216.2%₩17.0bn
margin 47.0%
₩16.1bn

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

EuBiologics top stories 2 weeks, by number of outlets

  1. 1
    WHO 사무총장, 유바이오로직스 춘천공장 방문…백신 공급 현황 점검
    4 outlets · 4 articlesFirst report Oct 22 12:00 이데일리
  2. 2
    유바이오로직스, 대상포진 백신 국내 임상 1상 결과 발표
    3 outlets · 4 articlesFirst report Oct 21 17:55 CBC뉴스Clinical trial
  3. 3
    유바이오로직스, 105억 규모 경구용 콜레라 백신 납품 계약
    3 outlets · 4 articlesFirst report Oct 26 11:28 뉴시스경제Order / supply contract
  4. 4
    유바이오로직스, 3분기 최대 실적 전망…백신 사업 다변화
    3 outlets · 3 articlesFirst report Oct 30 10:21 메디파나뉴스
  5. 5
    "유바이오로직스, 3분기 실적 반등 전망"
    3 outlets · 3 articlesFirst report Oct 27 08:07 아시아경제
  6. 6

Latest EuBiologics news Korean headlines